Table 1.
Characteristics of the included patients (n = 340)
| Total | Noninfectious ILD | P‐value | ||
|---|---|---|---|---|
| No, n (%) | Yes, n (%) | |||
| Gender, Female | 130 (38.2) | 123 (37.0) | 7 (87.5) | 0.006 |
| Median age at HSCT (IQR), years | 3 (1–7) | 3 (1–7) | 3 (2–3) | 0.113 |
| Median follow‐up to event after HSCT (IQR), months | 54 (15–96) | 54 (15–96) | 30 (9–61) | 0.168 |
| Median days to neutrophil engraftment (IQR) | 10 (9–11) | 10 (9–11) | 10 (8–12) | 0.530 |
| Median days to platelet engraftment (IQR) | 22 (17–30) | 22 (17–31) | 21 (19–28) | 0.968 |
| Diagnosis | 0.613 | |||
| Neuroblastoma | 158 (46.5) | 152 (45.8) | 6 (75.0) | |
| Medulloblastoma | 62 (18.2) | 60 (96.7) | 2 (2.5) | |
| Sarcoma | 24 (7.1) | 24 (100) | 0 (0.0) | |
| Retinoblastoma | 24 (7.0) | 24 (100) | 0 (0.0) | |
| Wilms' tumour | 12 (3.5) | 12 (100) | 0 (0.0) | |
| Germ cell tumour | 9 (2.6) | 9 (100) | 0 (0.0) | |
| Other brain tumour | 51 (15.0) | 51 (100) | 0 (0.0) | |
| Total body irradiation | 74 (21.7) | 70 (21.1) | 2 (25.0) | 0.678 |
| Thoracic RT | 130 (38.2) | 125 (37.7) | 4 (50.0) | 0.484 |
| MIBG treatment | 39 (11.5) | 33 (9.9) | 3 (37.5) | 0.042 |
| IL‐2 treatment | 45 (13.2) | 41 (12.3) | 3 (37.5) | 0.071 |
| Number of HDCT treatments | 0.209 | |||
| Once | 85 (25.0) | 85 (25.6) | 0 (0.0) | |
| Twice | 255 (75.0) | 247 (74.4) | 8 (100) | |
| HDCT regimen used in the first or second autologous HSCT session | 0.559 | |||
| CyM | 119 (35.0) | 117 (20.2) | 2 (12.5) | |
| CECy | 110 (32.4) | 104 (18.0) | 6 (37.5) | |
| CTE | 100 (29.4) | 100 (17.3) | 0 (0.0) | |
| TM | 96 (28.2) | 91 (15.7) | 5 (31.3) | |
| CEM | 63 (18.5) | 62 (10.7) | 1 (6.3) | |
| CE | 60 (17.6) | 60 (10.4) | 0 (0.0) | |
| BM | 24 (7.1) | 23 (4.0) | 1 (6.3) | |
| CTM | 17 (5.0) | 17 (2.9) | 0 (0.0) | |
| CT | 2 (0.6) | 1 (0.2) | 1 (6.3) | |
| TE | 2 (0.6) | 2 (0.3) | 0 (0.0) | |
| M | 1 (0.3) | 1 (0.2) | 0 (0.0) | |
| CEI | 1 (0.3) | 1 (0.2) | 0 (0.0) | |
BM, busufan and melphalan; CE, carboplatin and etoposide; CECy, carboplatin, etoposide and cyclophosphamide; CEI, carboplatin, etoposide and ifosfamide; CEM, carboplatin, etoposide and melphalan; CT, carboplatin and theiotepa; CTE, carboplatin, thiotepa and etoposide; CTM, carboplatin, thiotepa and melphalan; CyM, cyclophosphamide and melphalan; HDCT, high‐dose chemotherapy; HSCT, haematopoietic stem cell transplantation; IL, interleukin; IQR, interquartile range; M, melphalan; MIBG, iodine‐131‐meta‐iodobenzylguanidine; RT, radiation therapy; TE, thiotepa and etoposide; TM, thiotepa and melphalan., ,